Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182 is registered in ClinicalTrials.gov with Lumen Bioscience, Inc. as lead sponsor.

NCT NCT05330182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05330182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Lead sponsor
Lumen Bioscience, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 29, 2024
Completion date
December 1, 2026
Enrollment
375 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

clostridioides difficile infection